$500,000 in AbbVie and Gilead Could Pay More Than $11,000 a Year in Dividends

Published November 21, 2026, 1:07pm ET · 3 min read

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

A modern, multi-story glass building with a blue-tinted facade and the white 'abbvie' logo prominently displayed near the top. The building features numerous reflective windows, and a clear blue sky is visible above. Green trees are seen at the base of the building, with a portion of a lighter-colored building to the right.
The modern corporate headquarters of AbbVie, a pharmaceutical giant, symbolizes the company's strong foundation. Its consistent performance makes it a compelling long-term buy despite recent market volatility. © vzphotos / iStock Editorial via Getty Images

A retiree who lives on portfolio withdrawals wants to know one thing above all: will the next deposit arrive, and will it be a little bigger than the last one? Large drugmakers have a strong case here. People fill prescriptions for HIV and autoimmune disease in recessions and in bull markets, and patented medicines bring in margins high enough to fund dividends that rise year after year.

Splitting $500,000 evenly puts $250,000 into each of two pharmaceutical dividend payers. At current forward yields, the pair would produce an estimated $11,000 or more in annual passive income. That figure is an estimate and could change. Below is the income from a $250,000 stake in each name, listed from the lower yield to the higher one.

Gilead Sciences

Gilead’s business runs on its HIV franchise. HIV sales came to $6.249B (+18%)[1] in the third quarter, out of total revenue of $8.30B. Yeztugo, the twice-yearly PrEP shot, brought in $305M versus $39M[1] in the same quarter a year earlier. The yield is low partly because the stock has climbed 38.03% year to date. The dividend rose from $0.79 to $0.82 per quarter beginning in March 2026, a 3.8% increase.

On a GAAP-style earnings basis, coverage looks broken. Gilead expects a full-year non-GAAP loss of $(1.20)-$(0.85) per share because of roughly $12.4B in acquired IPR&D charges. The cash flow numbers look much better. Third-quarter free cash flow of $4.798B[1] covered dividends paid several times over, since the payout took about 21.7% of it. Debt was $26.2B against $6.4B in cash at the end of September. The main risk is concentration in a single franchise: Biktarvy faces a Medicare negotiated price starting January 1, 2028, and the acquired pipeline assets still have to justify their clinical-trial costs.

GILD price target

AbbVie

  • Stock #1: AbbVie (NYSE:ABBV)
  • Forward Yield: 2.53%
  • Shares for $250,000: 869.50
  • Annual Passive Income: ~$6,330

AbbVie has rebuilt its immunology business since Humira lost exclusivity. Skyrizi brought in $5.776B (+22.7%) in the third quarter, and Rinvoq added $2.706B (+23.9%), lifting total revenue 10.3%. On October 30, AbbVie raised its quarterly dividend from $1.73 to $1.82, about 5.2%. The new rate is payable February 16, 2027. The company also announced a bispecific cancer drug deal with Germany’s Disco this week.

Coverage is solid. The $7.28 annualized dividend equals about 52% of the company’s raised full-year adjusted EPS guidance of $13.95-$13.99. Dividends paid used about 42% of third-quarter free cash flow. The balance sheet is the weak point.

Total debt rose to $80.9B from $70.8B one quarter earlier, and shareholder equity is negative at -$4.58B. Patent expirations are the specific risk to track. Humira sales fell 31.2% as biosimilars spread, and drug pricing reform could squeeze the products that replaced it.

ABBV price target

Income Breakdown From a $500,000 Pharma Pair

Name Forward Yield Annual Dividend Income
Gilead Sciences 1.97% $4,927
AbbVie 2.53% $6,330
Total 2.25% $11,257

Can Two Drugmakers Carry a Retiree’s Income Plan?

Together, these 2 positions would generate an estimated $11,257 in annual passive income on a $500,000 investment, for a blended yield of 2.25%. Gilead accounts for $4,927 of that, and AbbVie supplies the remaining $6,330.

Drugmakers can pay reliable dividends because patented medicines generate high margins and need little capital spending. That support weakens when patents expire or when price negotiations cut into a top seller. For a retiree, this pair offers well-covered payouts that keep growing, but the starting yield is modest. Holding only two stocks from one industry also means a single pricing law or failed trial could affect both income streams at once. Dividends that rise every year help income keep pace with inflation, and that is the whole point of a dividend ladder built so you never have to sell a share- the setup we walked through in a free guide here.

Contact [email protected] for any questions or corrections.

Chris Lange

Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.

His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.

When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.

All articles →

Sources

  1. Gilead Sciences Form 8-K (Q3 FY2026)U.S. Securities and Exchange Commission